» Articles » PMID: 26209294

Salinomycin Radiosensitizes Human Nasopharyngeal Carcinoma Cell Line CNE-2 to Radiation

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2015 Jul 26
PMID 26209294
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Nasopharyngeal carcinoma (NPC) is primarily treated by chemoradiation. However, how to promote radiation sensitivity in NPC remains a challenge. Salinomycin is potentially useful for the treatment of cancer. This study aimed to explore the radiosensitivity of salinomycin on human nasopharyngeal carcinoma cell line CNE-2. CNE-2 were treated with salinomycin or irradiation, alone or in combination. The cytotoxicity effects of salinomycin were measured using CCK-8 assay. Clonogenic survival assay was used to evaluate the effects of salinomycin on the radiosensitivity of CNE-2. The changes of cell cycle distribution and apoptosis were assayed using flow cytometry. The expression of Caspase3/Bax/Bal-2 was detected by Western blotting. DNA damage was detected via γ-H2AX foci counting. The results showed that salinomycin induced apoptosis and G2/M arrest, increased Bax and cleaved Caspase3, decreased Bcl-2 expression, and increased the formation of γ-H2AX nuclear foci. These data suggest that salinomycin may be a radiosensitizer for NPC radiotherapy.

Citing Articles

Radiosensitivity-Related Genes and Clinical Characteristics of Nasopharyngeal Carcinoma.

Dai Y, Zhang Y, Yang M, Zhou L, Pan H, Xiao T Biomed Res Int. 2020; 2020:1705867.

PMID: 33299859 PMC: 7704138. DOI: 10.1155/2020/1705867.


Enhanced anticancer effect of oncostatin M combined with salinomycin in CD133 HepG2 liver cancer cells.

Fu C, Wang L, Tian G, Zhang C, Zhao Y, Xu H Oncol Lett. 2019; 17(2):1798-1806.

PMID: 30675240 PMC: 6341778. DOI: 10.3892/ol.2018.9796.


PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis.

Ji Y, Li H, Wang F, Gu L Front Pharmacol. 2018; 9:648.

PMID: 30002625 PMC: 6031703. DOI: 10.3389/fphar.2018.00648.


Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review.

Jiang J, Li H, Qaed E, Zhang J, Song Y, Wu R J Exp Clin Cancer Res. 2018; 37(1):26.

PMID: 29433536 PMC: 5809980. DOI: 10.1186/s13046-018-0680-z.


Effects of salinomycin and 17‑AAG on proliferation of human gastric cancer cells in vitro.

Zhang Z, Zhao J, Mi Z, Pang Q, Wang A, Chen M Mol Med Rep. 2017; 16(2):1063-1070.

PMID: 28627587 PMC: 5562019. DOI: 10.3892/mmr.2017.6735.

References
1.
Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C . Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010; 394(4):1098-104. DOI: 10.1016/j.bbrc.2010.03.138. View

2.
Riccioni R, Dupuis M, Bernabei M, Petrucci E, Pasquini L, Mariani G . The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010; 45(1):86-92. DOI: 10.1016/j.bcmd.2010.03.008. View

3.
Danforth H, Ruff M, REID W, Johnson J . Anticoccidial activity of salinomycin in floor-pen experiments with broilers. Poult Sci. 1977; 56(3):933-8. DOI: 10.3382/ps.0560933. View

4.
Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C . Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009; 390(3):743-9. DOI: 10.1016/j.bbrc.2009.10.042. View

5.
Akervall J, Nandalur S, Zhang J, Qian C, Goldstein N, Gyllerup P . A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 2013; 50(3):570-81. DOI: 10.1016/j.ejca.2013.11.007. View